Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Solskin Aerovate Therapeutics, Inc. (NASDAQ:AVTE) is developing a drug known as AV-101, which is being used to treat patients with pulmonary arterial hypertension [PAH]. The use of this inhaled drug is being explored in the ongoing phase 2b/3 IMPAHCT trial. Speaking of inhaled drug, this is highly promising. The reason why I say that is because AV-101 is an inhaled version of imatinib. It had done well in clinical trial when given to patients orally, but the problem was systemic side effects. This is wh ...